Advertisement

Topics

Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval

13:44 EDT 7 Aug 2017 | Topix

Morgan Stanley reduced its price target on the shares of Mylan N.V. following downward revision to its estimates due to the IMS trends, generic price pressure and uncertain new launch timing. Meanwhile, in a separate note, Mylan announced its NDA for TLD, a combo of Lamivudhine and Tenofovir Disoproxil Fumarate tablets, has received tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief, or PEPFAR.

Original Article: Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval

NEXT ARTICLE

More From BioPortfolio on "Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...